An Introduction to Efficacy Endpoints in Oncology Clinical Trials [Video]

Efficacy endpoints in oncology clinical trials define how treatment benefit is assessed. This video explains how endpoints such as overall survival, progression-free survival, objective response rate, disease-free survival, event-free survival, symptom endpoints, and quality-of-life measures shape what a cancer trial can claim.

WHAT THIS VIDEO COVERS
• How efficacy endpoints define treatment benefit in oncology studies
• Why overall survival is direct, but not always practical for every trial
• What progression-free survival measures, and why scan timing and censoring rules matter
• How objective response rate and RECIST criteria are used to assess tumour response
• Where disease-free survival and event-free survival fit in adjuvant and neoadjuvant settings
• Why symptom and quality-of-life endpoints need careful planning and interpretation

Endpoint choice affects study design, data collection, analysis, and how results are communicated. Earlier endpoints can provide useful evidence, but interpretation needs to stay close to what was actually measured, especially when tumour control or delayed progression could be mistaken for extended survival.

Quanticate’s statistical consultancy team helps sponsors plan endpoints that fit the treatment setting, clinical question and data available, from protocol input and SAP development through to analysis, interpretation and reporting. Request a consultation and a member of our team will be in touch.